AR073396A1 - Derivados de 3-amino-indazol o de 3-amino-4, 5, 6, 7-tetrahidro-indazol - Google Patents
Derivados de 3-amino-indazol o de 3-amino-4, 5, 6, 7-tetrahidro-indazolInfo
- Publication number
- AR073396A1 AR073396A1 ARP090103663A ARP090103663A AR073396A1 AR 073396 A1 AR073396 A1 AR 073396A1 AR P090103663 A ARP090103663 A AR P090103663A AR P090103663 A ARP090103663 A AR P090103663A AR 073396 A1 AR073396 A1 AR 073396A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- substituted
- cycloalkyl
- alkoxy
- hydroxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Estos compuestos son moduladores del FXR y pueden utilizarse como medicamentos utiles para disminuir la absorcion de colesterol, se disminuye el colesterol LDL y los triglicéridos y se reduce la ateroesclerosis inflamatoria. Reivindicacion 1: Compuestos de la formula (1) en la que R1 es un anillo elegido entre el grupo formado por fenilo, naftilo y heteroarilo, dicho anillo está sin sustituir o sustituido por 1-3 sustituyentes elegidos con independencia entre el grupo formado por alquilo inferior, halogeno, halogenoalquilo inferior, hidroxi, alcoxi inferior, halogenoalcoxi inferior y ciano; R2, R3, R4 y R5 se eligen con independencia entre si entre el grupo formado por hidrogeno, halogeno y alquilo inferior; R2' y R3' juntos así como R4' y R5' juntos se reemplazan por un doble enlace, o R2', R3', R4' y R5' son hidrogeno; R6 se elige entre el grupo formado por alquilo inferior, cicloalquilo, alcoxialquilo inferior, fenilo sin sustituir o fenilo sustituido por 1-3 sustituyentes elegidos con independencia entre el grupo formado por alquilo inferior, halogeno, halogenoalquilo inferior, hidroxi, alcoxi inferior, halogenoalcoxi inferior, carboxilo, (alcoxi inferior)-carbonilo, alcoxicarbonilalquilo inferior, carboxilalcoxi inferior, alcoxicarbonilalcoxi inferior y ciano, fenilalquilo inferior, cuyo fenilo está sin sustituir o sustituido por 1-3 sustituyentes elegidos con independencia entre el grupo formado por alquilo inferior, halogeno, halogenoalquilo inferior, hidroxi, alcoxi inferior, halogenoalcoxi inferior y ciano, heterociclilo y heteroarilo sin sustituir o heteroarilo sustituido por 1-3 sustituyentes elegidos con independencia entre el grupo formado por alquilo inferior, halogeno, halogenoalquilo inferior, hidroxi, alcoxi inferior, halogenoalcoxi inferior y ciano; R7 se elige entre el grupo formado por hidrogeno, -C(O)-NH-R8, -C(O)-R9, -S(O)2-R10 y -C(O)-OR11; R8 se elige entre el grupo formado por alquilo inferior, cicloalquilo, cicloalquilo inferior, cicloalquilo sustituido por hidroxi, carboxilo, tetrazolilo o carboxilalquilo inferior, heterociclilo, fenilo sin sustituir y fenilo sustituido por 1-3 sustituyentes elegidos con independencia entre el grupo formado por alquilo inferior, halogeno, halogenoalquilo inferior, hidroxi, alcoxi inferior, halogenoalcoxi inferior, carboxilo, tetrazolilo, (alcoxi inferior)-carbonilo, alcoxicarbonilalquilo inferior, carboxilalquilo inferior, carboxilalcoxi inferior, alcoxicarbonilalcoxi inferior, ciano y cicloalquiloxi, cuyo resto cicloalquilo está sustituido por carboxilo; R9 se elige entre el grupo formado por alquilo inferior, cicloalquilo, cicloalquilo inferior y fenilalquilo inferior, cuyo fenilo está sin sustituir o sustituido por 1-3 sustituyentes elegidos con independencia entre el grupo formado por alquilo inferior, halogeno, halogenoalquilo inferior, hidroxi, alcoxi inferior, halogenoalcoxi inferior, carboxilo, tetrazolilo, (alcoxi inferior)-carbonilo, alcoxicarbonilalquilo inferior, carboxilalquilo inferior, carboxilalcoxi inferior, alcoxicarbonilalcoxi inferior, ciano y cicloalquiloxi, cuyo resto cicloalquilo está sustituido por carboxilo; R10 se elige entre el grupo formado por alquilo inferior, cicloalquilo, cicloalquilo inferior y fenilalquilo inferior, cuyo fenilo está sin sustituir o sustituido por 1-3 sustituyentes elegidos con independencia entre el grupo formado por alquilo inferior, halogeno, halogenoalquilo inferior, hidroxi, alcoxi inferior, halogenoalcoxi inferior, carboxilo, tetrazolilo, (alcoxi inferior)-carbonilo, alcoxicarbonilalquilo inferior, carboxilalquilo inferior, carboxilalcoxi inferior, alcoxicarbonilalcoxi inferior, ciano y cicloalquiloxi cuyo resto cicloalquilo está sustituido por carboxilo; y R11 se elige entre el grupo formado por alquilo inferior, cicloalquilo, cicloalquilo inferior, cicloalquilo sustituido por hidroxi, carboxilo, tetrazolilo o carboxilalquilo inferior, heterociclilo, fenilo sin sustituir y fenilo sustituido por 1-3 sustituyentes elegidos con independencia entre el grupo formado por alquilo inferior, halogeno, halogenoalquilo inferior, hidroxi, alcoxi inferior, halogenoalcoxi inferior, carboxilo, tetrazolilo, (alcoxi inferior)-carbonilo, alcoxicarbonilalquilo inferior, carboxilalquilo inferior, carboxilalcoxi inferior, alcoxicarbonilalcoxi inferior, ciano y cicloalquiloxi, cuyo resto cicloalquilo está sustituido por carboxilo; o las sales farmacéuticamente aceptables de los mismos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08165137 | 2008-09-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR073396A1 true AR073396A1 (es) | 2010-11-03 |
Family
ID=41382044
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090103663A AR073396A1 (es) | 2008-09-25 | 2009-09-23 | Derivados de 3-amino-indazol o de 3-amino-4, 5, 6, 7-tetrahidro-indazol |
Country Status (14)
Country | Link |
---|---|
US (1) | US8153663B2 (es) |
EP (1) | EP2346834B1 (es) |
JP (1) | JP5450632B2 (es) |
KR (1) | KR101444988B1 (es) |
CN (1) | CN102164900B (es) |
AR (1) | AR073396A1 (es) |
AU (1) | AU2009295967A1 (es) |
BR (1) | BRPI0919248A2 (es) |
CA (1) | CA2736434A1 (es) |
ES (1) | ES2443947T3 (es) |
IL (1) | IL211674A0 (es) |
MX (1) | MX2011002793A (es) |
TW (1) | TW201020234A (es) |
WO (1) | WO2010034657A1 (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010034649A1 (en) * | 2008-09-25 | 2010-04-01 | F. Hoffmann-La Roche Ag | 2,3-substituted indazole or 4,5,6,7-tetrahydro-indazoles as fxr modulators against dyslipidemia and related diseases |
US8252826B2 (en) * | 2010-03-24 | 2012-08-28 | Hoffmann-La Roche Inc. | Cyclopentyl- and cycloheptylpyrazoles |
US9012497B2 (en) | 2010-05-25 | 2015-04-21 | Symrise Ag | Cyclohexyl carbamate compounds as active anti-cellulite ingredients |
EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
WO2013037482A1 (en) | 2011-09-15 | 2013-03-21 | Phenex Pharmaceuticals Ag | Farnesoid x receptor agonists for cancer treatment and prevention |
JP6366721B2 (ja) | 2013-09-11 | 2018-08-01 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | B型肝炎ウイルス感染症を処置するための方法及び医薬組成物 |
MX2018015443A (es) | 2016-06-13 | 2019-04-11 | Gilead Sciences Inc | Compuestos moduladores de fxr (nr1h4). |
CA2968836A1 (en) | 2016-06-13 | 2017-12-13 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
WO2018153933A1 (en) | 2017-02-21 | 2018-08-30 | Genfit | Combination of a ppar agonist with a fxr agonist |
JP6906626B2 (ja) | 2017-03-28 | 2021-07-21 | ギリアード サイエンシーズ, インコーポレイテッド | 肝疾患を処置するための治療的組み合わせ |
JP2020515564A (ja) | 2017-03-30 | 2020-05-28 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | エピソーマルウイルスの持続性及び発現を低下させるための方法及び医薬組成物 |
BR112021011762A2 (pt) | 2019-01-15 | 2021-11-03 | Gilead Sciences Inc | Compostos para modulação de fxr (nr1h4) |
AU2020225225B2 (en) | 2019-02-19 | 2022-12-22 | Gilead Sciences, Inc. | Solid forms of FXR agonists |
JP2022540699A (ja) | 2019-07-18 | 2022-09-16 | ウエヌイグレックオ・ファーマ | インターフェロンの有害作用を減少させる方法 |
JP2023510274A (ja) | 2020-01-15 | 2023-03-13 | アンセルム(アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル) | D型肝炎ウイルスによる感染を処置するためのfxrアゴニストの使用 |
MX2023008365A (es) | 2021-01-14 | 2023-10-04 | Enyo Pharma | Efecto sinérgico de un agonista de fxr e ifn para el tratamiento de infección por hbv. |
CA3213217A1 (en) | 2021-04-28 | 2022-11-03 | Raphael Darteil | Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment |
CN113372276B (zh) * | 2021-05-25 | 2022-04-22 | 三峡大学 | 吲唑类衍生物及其应用 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1974379A (en) * | 1932-10-12 | 1934-09-18 | Cinch Mfg Corp | Coupling device for hose and like connections |
US1966325A (en) * | 1933-06-28 | 1934-07-10 | Verne E Welch | Pump |
GB865341A (en) * | 1958-07-30 | 1961-04-12 | Bayer Ag | 5-benzene-sulphonamido-1-phenyl pyrazole derivatives |
GB926327A (en) | 1960-05-13 | 1963-05-15 | Ici Ltd | New dyestuffs of the azostilbene series containing halopyrimidyl residues |
NL6707299A (es) * | 1966-07-16 | 1968-01-17 | ||
GB1145544A (en) | 1966-07-16 | 1969-03-19 | Polichimica Sap S P A | New tetrahydroindazoles |
KR20030011362A (ko) | 2000-06-23 | 2003-02-07 | 다케다 야쿠힌 고교 가부시키가이샤 | 벤즈옥사제피논 및 스쿠알렌 합성효소 저해제로서의 그의용도 |
US7112676B2 (en) | 2002-11-04 | 2006-09-26 | Hoffmann-La Roche Inc. | Pyrimido compounds having antiproliferative activity |
CN100448869C (zh) * | 2002-11-27 | 2009-01-07 | 拜尔药品公司 | 用于治疗糖尿病的苯胺基吡唑衍生物 |
AR042067A1 (es) | 2002-11-27 | 2005-06-08 | Bayer Pharmaceuticals Corp | Derivados de anilinopirazol utiles en el tratamiento de la diabetes |
WO2005063241A1 (ja) | 2003-12-26 | 2005-07-14 | Ono Pharmaceutical Co., Ltd. | ミトコンドリアベンゾジアゼピン受容体介在性疾患の予防および/または治療剤 |
CA2628260A1 (en) | 2005-11-09 | 2007-05-18 | Abbott Laboratories | 2-phenyl-2h-pyraz0le derivatives as p2x7 receptor antagonists and uses thereof |
US20110195110A1 (en) | 2005-12-01 | 2011-08-11 | Roger Smith | Urea compounds useful in the treatment of cancer |
-
2009
- 2009-09-15 ES ES09783046.7T patent/ES2443947T3/es active Active
- 2009-09-15 BR BRPI0919248A patent/BRPI0919248A2/pt not_active IP Right Cessation
- 2009-09-15 CN CN200980137912.0A patent/CN102164900B/zh not_active Expired - Fee Related
- 2009-09-15 EP EP09783046.7A patent/EP2346834B1/en not_active Not-in-force
- 2009-09-15 WO PCT/EP2009/061966 patent/WO2010034657A1/en active Application Filing
- 2009-09-15 KR KR1020117009165A patent/KR101444988B1/ko not_active IP Right Cessation
- 2009-09-15 AU AU2009295967A patent/AU2009295967A1/en not_active Abandoned
- 2009-09-15 MX MX2011002793A patent/MX2011002793A/es active IP Right Grant
- 2009-09-15 JP JP2011528291A patent/JP5450632B2/ja not_active Expired - Fee Related
- 2009-09-15 CA CA2736434A patent/CA2736434A1/en not_active Abandoned
- 2009-09-21 US US12/563,189 patent/US8153663B2/en not_active Expired - Fee Related
- 2009-09-22 TW TW098131981A patent/TW201020234A/zh unknown
- 2009-09-23 AR ARP090103663A patent/AR073396A1/es unknown
-
2011
- 2011-03-10 IL IL211674A patent/IL211674A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR101444988B1 (ko) | 2014-09-26 |
JP2012503618A (ja) | 2012-02-09 |
BRPI0919248A2 (pt) | 2019-09-24 |
EP2346834A1 (en) | 2011-07-27 |
JP5450632B2 (ja) | 2014-03-26 |
US8153663B2 (en) | 2012-04-10 |
WO2010034657A1 (en) | 2010-04-01 |
TW201020234A (en) | 2010-06-01 |
MX2011002793A (es) | 2011-04-05 |
ES2443947T3 (es) | 2014-02-21 |
US20100076026A1 (en) | 2010-03-25 |
CA2736434A1 (en) | 2010-04-01 |
EP2346834B1 (en) | 2013-11-20 |
IL211674A0 (en) | 2011-06-30 |
AU2009295967A1 (en) | 2010-04-01 |
CN102164900B (zh) | 2014-04-16 |
CN102164900A (zh) | 2011-08-24 |
KR20110059890A (ko) | 2011-06-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR073396A1 (es) | Derivados de 3-amino-indazol o de 3-amino-4, 5, 6, 7-tetrahidro-indazol | |
AR073314A1 (es) | Derivados de indazol o de 4,5,6,7-tetrahidro-indazol | |
AR120855A1 (es) | Derivados de pirazolilo útiles como agentes anticancerígenos | |
CR10784A (es) | Nuevos derivados de aminopirimidina como inhibidores de plki | |
PE20151781A1 (es) | Piridonamidas como moduladores de canales de sodio | |
PE20161405A1 (es) | Analogos de cortistatina y sintesis y usos de los mismos | |
AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
AR060525A1 (es) | Piridin [3,4-b] pirazinonas. composiciones farmaceuticas | |
PE20151951A1 (es) | Heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b | |
AR054024A1 (es) | Derivados de piridina -3- carboxamida como agonistas inversos de cb1 | |
MA34644B1 (fr) | Dérivés de pyrazole aminopyrimidine en tant que modulateurs du lrrk2 | |
CL2020001919A1 (es) | Inhibidores de endonucleasa cap-dependientes. | |
AR072962A1 (es) | Derivados de pirimidin-4-ona sustituidos | |
PE20141682A1 (es) | Derivados de (4-fenilimidazol-2-il) etilamina utiles como moduladores de canal de sodio | |
MA35749B1 (fr) | Dérivés nucléosidiques 4'-azido, 3'-fluoro substitués en tant qu'inhibiteurs de la réplication de l'arn du vhc | |
AR069480A1 (es) | Derivados de 2-amino-pirimidina | |
PE20130155A1 (es) | Derivados de ariletinilo | |
AR082886A1 (es) | Compuestos y composiciones farmaceuticas que los contienen | |
ES2530943T3 (es) | Derivados de la cromenona con actividad antitumoral | |
CU24039B1 (es) | Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17 | |
UY29393A1 (es) | Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones. | |
CO6341581A2 (es) | Derivados de heteroarilo como inhibidores de dgat1 | |
AR083760A1 (es) | Agentes antibacterianos y composiciones farmaceuticas | |
PE20151060A1 (es) | Nuevos derivados de pirazina como agonistas del receptor cb2 | |
ECSP11011365A (es) | Sales de adición de aminas que contienen grupos hidroxilo y/o carboxílicos con derivados de ácido aminonicotínico como inhibidores de dhodh |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |